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Abstract
Background: Myeloproliferative neoplasms (MPNs), typically defined by myeloid proliferation and eosinophilia, and
are only rarely caused by platelet-derived growth factor receptor beta (PDGFRB) gene rearrangements.
Case presentation: Here, we report a unique case of MPN that is negative for eosinophilia and characterized by a
novel PDGFRB rearrangement. After cytogenetic analysis revealed a karyotype of t(5;17) (q32;q11), we used
fluorescence in situ hybridization to specifically identify the PDGFRB gene at 5q31-q33 as the gene that had been
translocated. Subsequently, RNA sequencing identified a new MYO18A-PDGFRB gene fusion. This fusion presented a
previously undescribed breakpoint composed of exon 37 of MYO18A and exon 13 of PDGFRB. Furthermore, both
RT-PCR and Bi-directional Sanger sequencing confirmed this out-of-frame fusion. Interestingly, we simultaneously
identified the presence of another three PDGFRB transcripts, all of which were in-frame fusions. After treating the
patient with imatinib, the t(5;17) translocation was no longer detected by conventional cytogenetics or by FISH,
and at the time of the last follow-up, the patient had been in complete remission for 26 months.
Conclusion: We prove that MYO18A-PDGFRB fusions are recurrent genetic aberrations involved in MPNs, and
identify multiple fusion transcripts with novel breakpoints.
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Background
Constitutive activation of protein tyrosine kinases is a
common feature of the pathogenesis of chronic myelo-
proliferative neoplasms (MPNs). The genes most com-
monly involved in these neoplasms are those encoding
for the protein tyrosine kinases PDGFRA, PDGFRB,
FGFR1, KIT, FLT3, JAK2 and ABL1. In 2008 however,
the World Health Organization (WHO) classified rear-
rangements of PDGFRA, PDGFRB, and FGFR1 in a dis-
tinct disease category [1]. PDGFRB is a class III receptor
tyrosine kinase located on chromosome 5 at position
5q31-q33. The most common type of PDGFRB aberration
is a fusion translocation. To date, more than 30 different
PDGFRB fusion partners have been identified [2, 3], with
the majority of them only occurring in individual patients.
Nonetheless, a few of these fusions - for example, ETV6-
PDGFRB, H4-PDGFRB, and CCDC88C-PDGFRB [2, 4–6]
– are in fact recurrent. Interestingly, each partner typically
contains an oligomerization motif that contributes to
protein dimerization and consequently to the constitutive
activation of the PDGFRB kinase domain. Imatinib, a tyro-
sine kinase inhibitor typically used to treat those myeloid
tumors characterized by PDGFRB fusions, is reported to
produce sustained remission in nearly all cases [2, 3].
MYO18A, a member of the myosin superfamily origin-
ally identified in bone marrow stromal cells, is associated
with the ability of these cells to support hematopoiesis [7].
In hematological malignancies, MYO18A has been found
as fusions with FGFR1, PDGFRB, and in only a single case,
with MLL, leading to the 8p11 myeloproliferative
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syndrome (EMS), eosinophilia-associated MPN (MPN-
eo), and acute myeloid leukemia (AML) respectively
[8–10].
Here, we present a novel case of MPN in which a
unique MYO18A-PDGFRB fusion results in MPN with-
out eosinophilia. To the best of our knowledge, this is
the first time that fusion to exon 13 of PDGFB has been
reported. Interestingly, this patient harbored multiple
MYO18A-PDGFRB transcripts, with most of them being
in-frame fusions. Therapeutically, this patient was sensitive
to imatinib, and achieved both complete hematological
remission (CHR) and complete cytogenetic remission
(CCyR) in a sustained and rapid manner.
Case presentation
A 25-year-old man was admitted to our medical center
after experiencing prolonged weakness and splenomegaly.
A complete blood cell analysis indicated a white blood cell
count of 81,190/μL, a platelet count of 206,000/μL, and a
hemoglobin concentration of 10.5 g/dL. Peripheral blood
analysis showed all stages of neutrophilic maturation, with
1% myeloblasts, 4% promyelocytes, 10% myelocytes, 17%
metamyelocytes, 2% eosinophils and 9% basophils. Bone
marrow aspirates revealed that the patient was in the
chronic phase of chronic myeloid leukemia (CML), with
2.5% myeloblasts, 5.5% promyelocytes, 13% myelocytes,
13% metamyelocytes, 1.5% eosinophils and 9% basophils.
A multiplex PCR screen for gene fusions typical of
leukemia was negative. Chromosome analysis of the bone
marrow showed the presence of 46,XY,t (5;17) (q32;q11)
[10]. Subsequently, dual-color fluorescent in situ
hybridization (FISH) proved positive for PDGFRB gene
rearrangement. After one week of imatinib treatment at
400 mg/day, the patient achieved CHR. This dosage was
then decreased to 200 mg/day, and the patient acquired
CCyR three months later. Thereafter, the patient took
100 mg/day, and at the final follow-up (26 months later),
the patient still remained in complete remission.
Results
Through retrospective analysis, we identified an MPN
patient with a karyotype of 46,XY,t(5;17) (q32;q11)
(Fig. 1a). This suggested a rearrangement of the
PDGFRB gene located at chromosome 5q31-q33. In
order to confirm the suspected rearrangement, we
performed FISH analysis using two distinct probes com-
plementary to the 5’ and 3’ regions of the PDGFRB gene,
and found separated signals in 75% of blast cells (Fig. 1b).
Fig. 1 Multiple MYO18A-PDGFRB fusion transcripts in a myeloproliferative neoplasm patient with t(5;17) (q32;q11) (a) The R-banded karyotype
showing the translocation t(5;17) (q32;q11). The arrows indicate the structural aberrations of chromosomes 5 and 17; (b) FISH using Vysis LSI
PDGFRB Spectrum Green and Orange Probes. A yellow signal denotes a normal PDGFRB gene (5’and 3’regions remain joined), whereas orange
and green signals respectively denote the 5’ and 3’ regions of the PDGFRB gene after rearrangement; (c) Bi-directional Sanger sequencing of the
PCR product confirms the fusion between MYO18A exon 37(NM_078471.3) and PDGFRB exon 13(NM_002609.3); (d) Four distinct types of
MYO18A-PDGFRB fusion transcripts were detected in the patient
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A previous study by Walz et al. found that translocation
events at 17q11 were associated with the MYO18A gene
[9]. RT-PCR using MYO18A (exon 40) and PDGFRB
(exon 10) primers was unable to detect this previously re-
ported MYO18A-PDGFRB fusion transcript (data not
show) [9]. Whole transcriptome sequencing, however, un-
covered a fusion between exon 37 of MYO18A
(NM_078471.3) and exon 13 of PDGFRB (NM_002609.3).
Subsequently, RT-PCR and Bi-directional Sanger sequen-
cing confirmed this out-of-frame fusion betweenMYO18A
exon 37 and PDGFRB exon 13 (Fig. 1c). Given that the pa-
tient was highly sensitive to imatinib-mediated PDGFRB
inhibition, but showed no other imatinib-related abnor-
malities, we hypothesized that there was some degree of
splicing taking place within the MYO18A-PDGFRB fusion.
In fact, we were able to amplify different products con-
taining the same fusion point by RT-PCR, and a total of
four types of MYO18A-PDGFRB fusion transcripts were
identified by Sanger sequencing (Fig. 1d). Three out of
four of these transcripts were actually in-frame PDGFRB
fusions and accounted for a total of 90.9% of the identified
transcripts (Fig. 1d). Two of the in-frame transcripts con-
tained a deletion of MYO18A exon 30, with one of them
also having parts of exons 36–37 deleted at the same time.
Finally, the third in−frame fusion transcript had an
insertion including part of MYO18A intron 39 and part of
PDGFRB exon 12 (Fig. 1d).
Discussion and Conclusion
Although PDGFRB fusions are rare, they can be ob-
served in a diverse range of hematological malignancies
including Ph-like acute lymphoblastic leukemia (ALL),
AML, and atypical CML. These fusions have an adult
male predominance, and are clinically defined by eosino-
philia and splenomegaly [2]. To date, more than 30
partner genes of PDGFRB have been identified [2, 3].
However, only a minority of these are recurrent (the
most common of which is ETV6-PDGFRB), with the
vast majority being reported in only individual cases.
Walz et al. reported the first eosinophilia-associated
MPN attributed to a MYO18A-PDGFRB fusion in 2009
[9]. Here, we report another case of MPN that is charac-
terized by unique MYO18A-PDGFRB fusions and an
eosinophilia-free phenotype. In agreement with other
studies, this suggests that eosinophilia is a prominent,
but not invariable feature [11].
Interestingly, in the present case exon 37 of MYO18A
became fused in an out-of-frame fashion to exon 13 of
PDGFRB. However, as the patient was highly sensitive to
imatinib treatment - a pharmaceutical drug which
inhibits activated receptor tyrosine kinases including
PDGFRB - and displayed no other abnormalities, we
suspected that the patient harbored different spliced
versions of the fusion. Indeed, RT-PCR and sequencing
enabled us to identify four types of fusion transcripts in
our patient, with three of them being in-frame fusions.
Interestingly, PDGFRB fusions principally involve exons
11 and 12, and more rarely exons 9 and 10 [9, 12]. In
fact, there is no previous report of exon 13 being
involved in the fusion point, possibly due to it being an
out-of-frame fusion. The in-frame MYO18A-PDGFRB
fusion proteins included the majority of the domains of
MYO18A, including some of the coiled-coil motifs, and
the entire tyrosine kinase domain of PDGFRB. It is known
that only one, or a few of these coiled-coil motifs are
enough to promote the dimerization or oligomerization of
MYO18A-PDGFRB fusions. As in the case of the
MYO18A-FGFR1 fusion, this leads to constitutive activa-
tion of the tyrosine kinase domain [8]. In addition, the
lack of the PDGFRB transmembrane domain, which is
found in exon 11, results in delocalization of the fu-
sion protein to the cytoplasm. This may be another
mechanism through which the kinase domain be-
comes constitutively activated. Furthermore, deletion
of exon 12, which results in the disruption of the
autoinhibitory WW-like domain of the juxtamem-
brane region, may also promote transformation prop-
erties of such fusion proteins [13–15]. Of course,
however, loss of these domains is not mandatory for
transformation because in previous cases, other
MYO18A-PDGFRB fusions retained both the trans-
membrane and juxtamembrane domains.
Although PDGFRB fusions are rare, the identification
of PDGFRB rearrangements is significant because of
their sensitive response to imatinib, especially with
respect to MPNs [16]. Moreover, both primary and
secondary resistance to imatinib seems to be very rare
[17, 18]. Due to its low incidence, a standard imatinib
dose and medication time for patients with PDGFRB
fusions has yet to be formally established in clinical
treatment. With the standard dosage used for CML as a
reference, patients are initially treated with 400 mg/day
[16, 19]. In fact, PDGFR fusions are much more sensitive
to imatinib than BCR-ABL1 fusions, at least in vitro. For
instance, the IC50 of imatinib for inhibiting the prolifer-
ation of ETV6-PDGFRB transformed cells is 7.5 nM, a
value significantly lower compared to the IC50 of 800
nM for BCR-ABL transformed cells [20, 21]. In our
case, imatinib at 400 mg/day brought about CHR in
only one week, and after decreasing the dosage, CCyR
was also obtained within three months. Thereafter,
complete remission remained stable, indicating that a
low dose of imatinib is appropriate for patients with
PDGFRB fusions.
Overall, our findings further emphasize the prominent
role of PDGFRB in the pathogenesis of MPNs, and high-
light the importance of accurate diagnosis and targeted
therapy.
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Methods
R-banding and karyotyping
At the time of diagnosis, the bone marrow cells were
cultured for 24 h and analyzed for standard cytogenetic
R-banding. The karyotype was described according to
the International System for Human Cytogenetic
Nomenclature (ISCN 2013).
Fluorescence in situ hybridization (FISH) analysis
FISH analysis was performed on metaphase spreads,
using the Vysis LSI PDGFRB Spectrum Orange and Green
Probes (Abbott Molecular, Illinois, USA) according to the
manufacturer’s instructions.
RNA sequencing
Whole transcriptome sequencing of bone marrow
mononuclear cells was performed, and transcription se-
quence data were generated by high-throughput RNA
sequencing (Illumina HiSeq 2500). The online software
deFuse was used for the discovery of fusion transcripts.
RT-PCR and Sanger sequencing
RNA was reverse transcribed with random hexamers
using standard techniques (Thermo Fisher), and the
following primer sets were used to detect MYO18A-
PDGFRB transcripts: MYO18A(c.5165) Forward (5′-AC
ATCGCCAAAGCCAAGA-3′) and PDGFRB(c.2014) Re-
verse (5′-GATGGGTCCTCCTTTGGT-3′) at an anneal-
ing temperature of 58 °C over 32 cycles; MYO18A(c.2524)
Forward (5′-CTGGCGTTTGACGACTTG-3′) and PDG
FRB(c.2739) Reverse (5′-CCGTTTGATGGCATTGTAG-
3′); and MYO18A(c.5436) Forward (5′-GGACAAGT
CCCTGGTGAGC-3′) and PDGFRB(c.3301) Reverse (5′-
CTACAGGAAGCTATCCTCTGC-3′) at an annealing
temperature of 55 °C over 35 cycles. PCR products were
analyzed by Bi-directional Sanger sequencing.
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